The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with China-based biotech firm BeiGene (NASDAQ: BGNE). The collaboration aims to capitalize on the respective strengths of both entities to advance the translation of scientific and technological achievements, foster talent cultivation and exchange, and co-construct innovation and translational research institutes. Financial details of the agreement were not disclosed.
Leveraging Policy and Technological Advantages
BeiGene plans to utilize the policy advantages offered by the Hainan Free Trade Port and Lecheng, combined with its own technological and resource strengths, to engage in “government industry university medical research” collaborations. These collaborations will focus on innovative projects from incubation through to clinical trial stages. By jointly establishing the Lecheng Medical Industry Transformation Platform, the partners will facilitate academic exchanges and the joint cultivation of scientific research talents.
Promoting Commercial Applications and Industry Development
The joint efforts aim to convert scientific and technological innovation achievements into commercially viable applications, thereby supporting the high-quality development of the medical tourism and biotech industry. This strategic partnership is expected to enhance the Hainan Boao Lecheng International Medical Tourism Pilot Zone’s reputation as a hub for medical innovation and excellence, while also bolstering BeiGene’s role as a leading biotech company in China.-Fineline Info & Tech
